When does Telix report earnings and why does it matter for TLX.AX stock

Telix has an earnings announcement set for **20 Jan 2026**. The report matters because management commentary on TLX591 and TLX250 development and commercial rollouts can shift revenue guidance and the premium valuation of TLX.AX stock.

What are the top financial figures to watch in the TLX.AX earnings report

Watch revenue, **EPS A$0.04**, operating cash flow per share and any guidance on commercial uptake. Valuation metrics like PE **277.50** and price-to-sales **3.16** will frame investor reactions to the results.

How does Meyka AI view TLX.AX stock ahead of earnings

Meyka AI rates TLX.AX **68.51/100 — Grade B, HOLD** and projects a yearly price of **A$13.28**. The model flags pipeline catalysts but notes high valuation and leverage as risks. Forecasts are model-based and not guarantees.

What are the main investment risks for TLX.AX stock right now

Primary risks are Phase III trial setbacks, slower-than-expected commercial adoption, reimbursement challenges and litigation headlines. These can compress the premium valuation and raise volatility for TLX.AX stock.

AU Stocks

15 Jan 2026 Telix (TLX.AX, ASX) A$11.10 ahead of earnings: key catalysts

ByHuzaifa Zahoor January 15, 2026January 15, 2026

TLX.AX stock trades at A$11.10 intraday on 15 Jan 2026 as Telix Pharmaceuticals (TLX.AX, ASX) heads into an earnings update scheduled for 20 Jan 2026. Investors will focus on clinical progress for TLX591 and TLX250, revenue per share trends, and whether guidance or commercial updates narrow the gap to prior highs. Volume is elevated at 2,049,443.00 shares versus average 1,777,974.00, signalling firm trader interest. This earnings spotlight explains the key metrics, risks and a Meyka AI model forecast ahead of the report.